Advaxis (ADXS) 10-K 11 Jan 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Oct. 31, 2018	Dec. 31, 2018	Apr. 30, 2018
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	1,100,397
Document Type	10-K
Document Period End Date	Oct. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 82,957,000
Entity Common Stock, Shares Outstanding		69,703,219
Trading Symbol	ADXS
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,018

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Oct. 31, 2018	Oct. 31, 2017
Current assets:
Cash and cash equivalents	$ 44,141	$ 23,900
Restricted cash	977	587
Short-term investment securities		46,398
Income tax receivable		4,453
Deferred expenses	2,072	2,986
Prepaid expenses and other current assets	3,275	2,919
Total current assets	50,465	81,243
Property and equipment (net of accumulated depreciation)	6,684	7,111
Intangible assets (net of accumulated amortization)	4,838	4,857
Other assets	280	431
Total assets	62,267	93,642
Current liabilities:
Accounts payable	5,646	5,121
Accrued expenses	6,185	8,700
Deferred revenue	4,476	6,995
Common stock warrant liability	6,517
Other current liabilities	48	48
Total current liabilities	22,872	20,864
Deferred revenue	14,189	17,479
Other liabilities	1,155	1,039
Total liabilities	38,216	39,382
Commitments and contingencies - Note 10
Shareholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2018 and 2017. Liquidation preference of $0 at October 31, 2018 and 2017.
Common stock - $0.001 par value; 95,000,000 shares authorized, 69,556,452 shares issued and outstanding at October 31, 2018 and 41,206,538 shares issued and outstanding at October 31, 2017.	70	41
Additional paid-in capital	391,638	355,361
Accumulated deficit	(367,657)	(301,142)
Total shareholders' equity	24,051	54,260
Total liabilities and shareholders' equity	$ 62,267	$ 93,642

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Oct. 31, 2018	Oct. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Series B Preferred stock, shares issued	0	0
Series B Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	69,556,452	41,206,538
Common stock, shares outstanding	69,556,452	41,206,538

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Income Statement [Abstract]
Revenue	$ 6,063	$ 12,031
Operating expenses:
Research and development expenses	56,970	70,508
General and administrative expenses	19,472	39,969
Total operating expenses	76,442	110,477
Loss from operations	(70,379)	(98,446)
Other income (expense):
Interest income	577	670
Net changes in fair value of derivative liabilities	3,400	20
Other expense	(63)	(82)
Net loss before income tax benefit	(66,465)	(97,838)
Income tax expense (benefit)	50	(4,403)
Net loss	$ (66,515)	$ (93,435)
Net loss per common share, basic and diluted	$ (1.29)	$ (2.31)
Weighted average number of common shares outstanding, basic and diluted	51,522,361	40,527,844

Statements of Shareholders' Equ

Statements of Shareholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Balance at Oct. 31, 2016		$ 40	$ 327,099	$ (130)	$ (207,707)	$ 119,302
Balance, shares at Oct. 31, 2016		40,057,067		(16,020)
Stock based compensation		$ 1	27,865			27,866
Stock based compensation, shares		1,030,507
Tax withholdings paid related to net share settlement of equity awards			(357)			(357)
Tax withholdings paid on equity awards			(997)	$ (881)		(1,878)
Tax withholdings paid on equity awards, shares				(128,613)
Tax shares sold to pay for tax withholdings on equity awards			843	$ 1,011		1,854
Tax shares sold to pay for tax withholdings on equity awards, shares				144,633
Common Stock issued upon exercise of warrants			1			1
Common Stock issued upon exercise of warrants, shares		225
Issuance of shares to employees under ESPP Plan			251			251
Issuance of shares to employees under ESPP Plan, shares		26,594
Advaxis at-the-market sales			656			656
Advaxis at-the-market sales, shares		92,145
Net Loss					(93,435)	(93,435)
Balance at Oct. 31, 2017		$ 41	355,361		(301,142)	54,260
Balance, shares at Oct. 31, 2017		41,206,538
Stock based compensation		$ 1	7,027			7,028
Stock based compensation, shares		762,448
Tax withholdings paid related to net share settlement of equity awards			(87)			(87)
Tax withholdings paid on equity awards			(474)			(474)
Tax shares sold to pay for tax withholdings on equity awards			460			460
Issuance of shares to employees under ESPP Plan			50			50
Issuance of shares to employees under ESPP Plan, shares		39,171
Advaxis at-the-market sales		$ 1	2,658			2,659
Advaxis at-the-market sales, shares		881,629
Advaxis Public Offering		$ 27	26,643			26,670
Advaxis Public Offering, shares		26,666,666
Net Loss					(66,515)	(66,515)
Balance at Oct. 31, 2018		$ 70	$ 391,638		$ (367,657)	$ 24,051
Balance, shares at Oct. 31, 2018		69,556,452

Statement of Cash Flows

Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
OPERATING ACTIVITIES
Net loss	$ (66,515)	$ (93,435)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	6,983	27,836
Employee stock purchase plan expense	7	80
Gain on change in value of warrants	(3,400)	(20)
Loss on disposal of property and equipment	614	3
Write-off of intangible assets	1,047	315
Depreciation expense	1,113	791
Amortization expense of intangible assets	388	330
Net (accretion) amortization of premiums and discounts	(6)	184
Change in operating assets and liabilities:
Prepaid expenses and other current assets	683	(1,972)
Income taxes receivable	4,453	(1,903)
Other assets	151	1,325
Accounts payable and accrued expenses	(1,954)	1,160
Deferred revenue	(5,809)	(11,781)
Other liabilities	116	245
Net cash used in operating activities	(62,129)	(76,842)
INVESTING ACTIVITIES
Restricted cash established with letter of credit agreement	(390)	(587)
Purchases of investments	(12,487)	(71,177)
Proceeds from maturities of short-term investment securities	58,891	63,930
Purchase of property and equipment	(1,425)	(3,449)
Cost of intangible assets	(1,416)	(1,173)
Net cash provided by (used in) investing activities	43,173	(12,456)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock and warrants	39,246	656
Proceeds from the exercise of warrants		1
Proceeds from employee stock purchase plan	52	171
Tax withholdings paid related to net share settlement of equity awards	(87)	(357)
Employee tax withholdings paid on equity awards	(474)	(1,878)
Tax shares sold to pay for employee tax withholdings on equity awards	460	1,854
Net cash provided by financing activities	39,197	447
Net increase (decrease) in cash and cash equivalents	20,241	(88,851)
Cash and cash equivalents at beginning of year	23,900	112,751
Cash and cash equivalents at end of year	44,141	23,900
Supplemental Disclosures of Cash Flow Information
Cash paid for taxes	50	50
Supplemental Schedule of Noncash Investing and Financing Activities
Accounts payable and accrued expenses settled with common stock		75
Property and equipment included in accounts payable and accrued expenses		$ 66

Nature of Operations and Basis

Nature of Operations and Basis of Presentation	12 Months Ended
	Oct. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Basis of Presentation	1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION Advaxis, Inc. (“Advaxis” or the “Company”) is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Listeria monocytogenes Lm Lm Lm Lm ● Alerting and training the immune system by activating multiple pathways in antigen-presenting cells (“APCs”) with the equivalent of multiple adjuvants; ● Attacking the tumor by generating a strong, cancer-specific T cell response; and ● Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells. Advaxis’ proprietary Lm Lm Going Concern and Managements Plans The Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for an extended period of time. The aforementioned factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date of filing. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern within one year after the date the financial statements are issued. Historically, our major sources of cash have comprised proceeds from various public and private offerings of our common stock, option and warrant exercises, and interest income. From October 2013 through October 2018, the Company raised approximately $265 million in gross proceeds from various public and private offerings of our common stock. As of December 31, 2018 and October 31, 2018, the Company had approximately $36.1 million and $45.1 million, respectively, in cash, restricted cash and cash equivalents. Management’s plans to mitigate an expected shortfall of capital, to support future operations, include raising additional funds. The actual amount of cash that it will need to operate is subject to many factors. The Company also recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Oct. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used when accounting for such items as the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), deferred expenses and deferred revenue, the fair value of options, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may or may not differ from estimates. Reclassification Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss. Collaboration Agreements The Company evaluates whether an arrangement is a collaborative arrangement under the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements, at its inception based on the facts and circumstances specific to the arrangement. The Company also reevaluates whether an arrangement qualifies or continues to qualify as a collaborative arrangement whenever there is a change in either the roles of the participants or the participants’ exposure to significant risks and rewards dependent on the ultimate commercial success of the endeavor. For those collaborative arrangements where it is determined that the Company is the principal participant, costs incurred and revenue generated from third parties are recorded on a gross basis in the financial statements. From time to time, the Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of products and product candidates. These collaborations generally provide for non-refundable, upfront license fees, research and development and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. The Company’s collaboration agreements with third parties are performed on a ‘‘best efforts’’ basis with no guarantee of either technological or commercial success. Revenue Recognition The Company has derived the majority of its revenue from patent licensing and research and development services associated with patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured. Revenue associated with nonrefundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected period of performance. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestones as revenue on a straight-line basis over the remaining expected performance period under the arrangement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s statements of operations. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, and the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received. Deferred revenue represents the portion of payments received for which the earnings process has not been completed. Deferred revenue expected to be recognized within the next 12 months is classified as a current liability. An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Concentration of Credit Risk The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $43.8 million is subject to credit risk at October 31, 2018. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk. Restricted Cash and Letter of Credit During July 2017 and January 2018, the Company established two letters of credit with a financial institution as security for the purchase of custom equipment and as security for application fees associated with the Company’s Marketing Authorization Application (“MAA”) in Europe. The letters of credit are collateralized by cash which is unavailable for withdrawal or for usage for general obligations. No amount is outstanding under either letter of credit as of October 31, 2018. Investments Investment securities consist of certificates of deposit, domestic governmental agency loans, and U.S. treasury notes. The Company classifies these securities as held-to-maturity. Held-to-maturity securities are those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method. A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in Other Income (Expense), net. The Company did not recognize any impairment charges during the years ended October 31, 2018 or 2017. Interest income is recognized when earned. Deferred Expenses Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operations as the research and development activity is performed. Property and Equipment Property and equipment is stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three to ten years. When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Intangible Assets Intangible assets are recorded at cost and include patents and patent application costs, licenses and software. Intangible assets are amortized on a straight-line basis over their estimated useful lives ranging from 3 to 20 years. Patent application costs are written-off if the application is rejected, withdrawn or abandoned. Impairment of Long-Lived Assets The company reviews its long-lived assets, including property and equipment and intangible assets, for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, an impairment loss is recognized in the Statement of Operations based on the excess of the carrying amount over the fair value of the asset. Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. In the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share. As of October 31, 2018 2017 Warrants 14,169,542 3,092,935 Stock options 4,951,049 3,893,558 Restricted stock units 489,270 1,363,119 Total 19,609,861 8,349,612 Research and Development Expenses Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs. Stock Based Compensation The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants. The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its common stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants. The Company accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants. Treasury Stock The Company accounts for repurchases of common stock and shares withheld in lieu of taxes when restricted stock vests using the cost method with common stock in treasury classified in the balance sheet as a reduction in shareholders’ equity. Fair Value of Financial Instruments The carrying value of financial instruments, including cash and cash equivalents, restricted cash and accounts payable approximated fair value as of the balance sheet date presented, due to their short maturities. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Monte Carlo valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date. Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized. Recent Accounting Standards In February 2016, the Financial Accounting Standards Board, or FASB, issued ASU, No. 2016-02, Leases (Topic 842), which establishes a comprehensive new lease accounting model. The new standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than 12 months. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018, with early adoption permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, an update which provides another transition method, in addition to the existing modified retrospective transition method, by allowing entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new standard changes the presentation of restricted cash and cash equivalents on the statement of cash flows. Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The amendments in this Update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of businesses. The amendments in this Update provide a screen to determine when a set is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. This Update is the final version of Proposed ASU 2015-330 Business Combinations (Topic 805) – Clarifying the Definition of a Business, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This Update is the final version of Proposed ASU 2016-360—Compensation—Stock Compensation (Topic 718)—Scope of Modification Accounting, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”), which expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted, but no earlier than our adoption of ASC 606. This ASU is not expected to have a material impact on the Company’s financial statements. Recently Adopted Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (“ASU 2016-08”); ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”); ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”); ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers (“ASU 2016-20”); Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842) (“ASU 2017-13”); and ASU 2017-14, Income Statement—Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) (“ASU 2017-14”). The Company must adopt ASU 2016-08, ASU 2016-10, ASU 2016-12, ASU 2016-20, ASU 2017-13 and ASU 2017-14 with ASU 2014-09 (collectively, the “new revenue standards”). The new revenue standards may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company has completed its assessment of the impact that the standard will have on revenue recognition. The Company has reviewed contracts for all material revenue streams and assessed potential impacts on the Company’s financial statements, results of operations, cash flows, disclosures, and internal controls over financial reporting. The Company currently recognizes most of its revenue over time. Management has determined that this will remain materially consistent upon adoption of the new standard and no adjustment to the Company’s financial position, results of operations, or cash flows will be necessary upon adoption. Additionally, the Company will make additional disclosures related to the revenues arising from contracts with customers as required by the new standard. The Company has adopted this guidance effective November 1, 2019 using the modified retrospective approach. In August 2014, the FASB issued ASU No. 2014-15, Disclosures of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, ending after December 15, 2016. The Company adopted this standard effective for the year ending October 31, 2017. There was no impact on the Company’s financial statements. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Equity from Liabilities (Topic 480) and Derivatives and Hedging (Topic 815) (“ASU 2017-11”), which addresses the complexity of accounting for certain financial instruments with down round features and finalizes pending guidance related to mandatorily redeemable noncontrolling interests. Under ASU 2017-11, when determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU 2017-11 becomes effective for annual reporting periods beginning after December 15, 2018, including interim periods thereafter; early adoption is permitted, including adoption in an interim period. The Company early adopted this standard utilizing the modified retrospective method, which is defined in ASU 2017-11 as, “retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s).” Since the Company didn’t have any financial instruments with a down round feature as of November 1, 2017, the beginning of the fiscal year of adoption, the adoption of this standard did not have an impact on the Company’s financial statements. In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606” (“ASU 2018-18”). The amendments in ASU 2018-18 make targeted improvements to generally accepted accounting principles (GAAP) for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this Update should be applied retrospectively to the date of initial application of Topic 606. The Company has adopted this guidance effective November 1, 2018 using the modified retrospective approach. There was no impact on the Company’s financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Investments

Investments	12 Months Ended
	Oct. 31, 2018
Schedule of Investments [Abstract]
Investments	3. INVESTMENTS The following table summarizes the Company’s investment securities at amortized cost as of October 31, 2017 (in thousands): October 31, 2017 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value Short-term investments: Certificates of Deposit $ 11,391 $ - $ - $ 11,391 Domestic Governmental Agency Loans 500 - - 500 U.S Treasury Notes 34,507 - 25 34,482 Total short-term investment securities $ 46,398 $ - $ 25 $ 46,373 As of October 31, 2018, all of the Company’s short-term investment securities have matured.

Property and Equipment

Property and Equipment	12 Months Ended
	Oct. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following (in thousands): October 31, 2018 2017 Leasehold improvements $ 2,321 $ 2,168 Laboratory equipment 5,510 4,381 Furniture and fixtures 746 729 Computer equipment 409 395 Construction in progress 17 645 Total property and equipment 9,003 8,318 Accumulated depreciation and amortization (2,319 ) (1,207 ) Net property and equipment $ 6,684 $ 7,111 Depreciation expense for the years ended October 31, 2018 and 2017 was approximately $1.1 million and $0.8 million, respectively. Laboratory equipment having a net book value of approximately $614,000 and $3,000 was disposed and was charged to research and development expenses in the statement of operations for the years ended October 31, 2018 and 2017, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Oct. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. INTANGIBLE ASSETS Intangible assets consist of the following (in thousands): October 31, 2018 2017 Patents $ 5,970 $ 5,727 License 777 777 Software 117 109 Total intangibles 6,864 6,613 Accumulated amortization (2,026 ) (1,756 ) Net intangible assets $ 4,838 $ 4,857 The expirations of the existing patents range from 2018 to 2038 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of approximately $1.0 million and $0.3 million and were abandoned and were charged to general and administrative expenses in the statement of operations for the years ended October 31, 2018 and 2017, respectively. Intangible asset amortization expense that was charged to general and administrative expense in the statement of operations was approximately $0.4 million and $0.3 million for the years ended October 31, 2018 and 2017, respectively. At October 31, 2018, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): 2019 $ 392 2020 376 2021 356 2022 356 2023 356 Thereafter 3,002 Total $ 4,838

Accrued Expenses

Accrued Expenses	12 Months Ended
	Oct. 31, 2018
Payables and Accruals [Abstract]
Accrued Expenses	6. ACCRUED EXPENSES: The following table represents the major components of accrued expenses (in thousands): October 31, 2018 2017 Salaries and other compensation $ 2,035 $ 2,653 Vendors 3,660 2,812 Professional fees 490 3,235 Total accrued expenses $ 6,185 $ 8,700

Common Stock Purchase Warrants

Common Stock Purchase Warrants and Warrant Liability	12 Months Ended
	Oct. 31, 2018
Common Stock Purchase Warrants And Warrant Liability
Common Stock Purchase Warrants and Warrant Liability	7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Warrants A summary of warrant activity was as follows (In thousands, except share and per share data): Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding and exercisable warrants at October 31, 2016 3,110,575 $ 5.04 1.91 $ 9,558 Exercised (225 ) 5.00 Expired (17,955 ) 11.43 Outstanding and exercisable warrants at October 31, 2017 3,092,395 $ 5.00 .92 $ - Issued 14,166,666 1.50 Expired (3,089,519 ) 5.00 Outstanding and exercisable warrants at October 31, 2018 14,169,542 $ 1.50 5.87 $ - At October 31, 2018, the Company had 2,876 of its total 14,169,542 outstanding warrants classified as equity (equity warrants). At October 31, 2017, the Company had all of its total 3,092,395 outstanding warrants classified as equity warrants. At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders equity section of the balance sheet. Warrant Liability At October 31, 2018, the Company had 14,166,666 of its total 14,169,542 outstanding warrants classified as liabilities (liability warrants). These warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of October 31, 2018, the down round feature was not triggered. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which net cash settlement would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. During the year ended October 31, 2018, 14,166,666 warrants were issued at an exercise price of $1.50 with a term of six years. The warrants were valued at approximately $9.9 million on the September 11, 2018 issuance using the Monte Carlo Model. In determining the fair warrant of the warrants issued on September 11, 2018, the Company used the following inputs in its Monte Carlo Model. Exercise price $0.85, stock price $1.50, expected term 6 years, volatility 99.21% and risk free interest rate 2.91%. At October 31, 2017, the Company had no outstanding warrants classified as liability warrants as the remaining liability warrants expired. The warrants required liability classification as the warranted contained a cash settlement provision in the event of a fundamental transaction. For the liability warrants that expired during the year ended October 31, 2017, the Company utilized the Black-Scholes Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. At October 31, 2018 and October 31, 2017, the fair value of the warrant liability was approximately $6.5 million and $0, respectively. For the years ended October 31, 2018 and 2017, the Company reported income of approximately $3.4 million and $20,000, respectively, due to changes in the fair value of the warrant liability. In measuring the warrant liability at October 31, 2018, the Company used the following inputs in its Monte Carlo Model: October 31 ,2018 Exercise Price $ 1.50 Stock Price $ 0.56 Expected Term 5.87 years Volatility % 97.47 % Risk Free Rate 3.03 %

Share Based Compensation

Share Based Compensation	12 Months Ended
	Oct. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share Based Compensation	8. SHARE BASED COMPENSATION The following table summarizes share-based compensation expense included in the statement of operations by expense category for the years ended October 31, 2018 and 2017 (in thousands): Year Ended October 31, 2018 2017 Research and development $ 2,836 $ 5,648 General and administrative 4,147 22,188 Total $ 6,983 $ 27,836 Amendments The Advaxis, Inc. 2015 Incentive Plan (the “2015 Plan”) was originally ratified and approved by the Company’s stockholders on May 27, 2015. Subject to proportionate adjustment in the event of stock splits and similar events, the aggregate number of shares of common stock that may be issued under the 2015 Plan is 3,600,000 shares, plus a number of additional shares (not to exceed 650,000) underlying awards outstanding as of the effective date of the 2015 Plan under the prior plan that thereafter terminate or expire unexercised, or are cancelled, forfeited or lapse for any reason. At the Annual Meeting of Stockholders of the Company held on March 10, 2016, the stockholders ratified and approved an amendment to the 2015 Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan from 3,600,000 shares to 4,600,000 shares. Furthermore, the stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 45,000,000 shares of common stock to 65,000,000 shares of common stock. At the Annual Meeting of Stockholders of the Company held on April 5, 2017, the stockholders ratified and approved an amendment to the 2015 Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan from 4,600,000 shares to 6,100,000 shares. The amendment also included a provision that provides for pre-defined annual increases in the number of shares available for issuance under the Plan equal to the lesser of: (i) 5% of the total number of shares of common stock outstanding, (ii) 2,500,000, or (iii) a lesser number determined by the Board of Directors. On January 1, 2018, 2,066,147 shares, or 5% of the total number of shares of common stock outstanding, were added to the 2015 Plan. At the Annual Meeting of Stockholders of the Company held on March 21, 2018, the stockholders ratified and approved an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 65,000,000 shares of common stock to 95,000,000 shares of common stock. As of October 31, 2018, there were 1,525,692 shares available for issuance under the 2015 Plan. Restricted Stock Units (RSUs) A summary of the Company’s RSU activity and related information for the year ended October 31, 2018 and 2017 is as follows: Number of RSU’s Weighted-Average Grant Date Fair Value Balance at October 31, 2016: 719,448 $ 10.77 Granted 1,632,134 7.90 Vested (877,383 ) 9.15 Cancelled (111,080 ) 8.74 Balance at October 31, 2017 1,363,119 $ 8.54 Granted 409,950 1.97 Vested (808,097 ) 7.71 Cancelled (475,702 ) 8.23 Balance at October 31, 2018 489,270 $ 4.69 The fair value of the RSUs as of the respective vesting dates was approximately $1.6 million and $6.0 million for the years ended October 31, 2018 and 2017 respectively. As of October 31, 2018, there was approximately $1.7 million of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.45 years. As of October 31, 2018, the aggregate intrinsic value of non-vested RSUs was approximately $275,000. Employee Stock Awards Common stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 733,105 shares (687,448 shares on a net basis after employee taxes) and 878,948 shares (834,600 shares on a net basis after employee taxes) during the years ended October 31, 2018 and 2017, respectively. Total stock compensation expense associated with these awards for the years ended October 31, 2018 and 2017 was approximately $3.1 million and $8.9 million, respectively. Included in compensation expense for the year ended October 31, 2018 was approximately $0.1 million and $0.3 million, respectively, recognized as a result of the modification of certain RSU’s associated with the resignation of the Company’s Chief Financial Officer in April 2018 and Chief Operating Officer in June 2018. Pursuant to the separation agreements, the vesting was accelerated on all of the outstanding RSU’s. Director Stock Awards During the years ended October 31, 2018 and 2017, common stock issued to the Directors for compensation related to board and committee membership was 75,000 shares and 30,000 shares, respectively. During the years ended October 31, 2018 and 2017, total stock compensation expense to the Directors was $0.2 million and $0.4 million, respectively. Stock Options A summary of changes in the stock option plan for the years ended October 31, 2018 and 2017 is as follows (In thousands, except share and per share data): Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding as of October 31, 2016 3,351,795 $ 13.31 7.82 $ 62 Granted 556,952 7.71 Cancelled or expired (15,189 ) 14.07 Outstanding as of October 31, 2017 3,893,558 $ 12.51 5.72 $ - Granted 2,518,060 2.06 Cancelled or expired (1,460,569 ) 9.14 Outstanding as of October 31, 2018 4,951,049 $ 8.19 6.56 $ - Vested and exercisable at October 31, 2018 2,827,171 $ 8.19 4.38 $ - The following table summarizes information about the outstanding and exercisable options at October 31, 2018: Options Outstanding Options Exercisable Weighted Weighted Weighted Weighted Average Average Average Average Exercise Number Remaining Exercise Intrinsic Number Remaining Exercise Intrinsic Price Range Outstanding Contractual Price Value Exercisable Contractual Price Value $ 0.60 - $4.99 2,037,108 9.53 $ 1.97 $ - 165,834 7.27 $ 3.22 $ - $ 5.00 - $9.99 526,029 5.20 $ 7.98 $ - 393,424 4.37 $ 8.07 $ - $ 10.00 - $14.99 2,199,592 4.42 $ 13.14 $ - 2,079,593 4.27 $ 13.16 $ - $ 15.00 - $21.25 188,320 3.07 $ 18.12 $ - 188,320 3.07 $ 18.12 $ - The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2018 and 2017 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s common stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s common stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating expected lives of the options. The Company used their own historical volatility in determining the volatility to be used. The expected term of the stock option grants was calculated using the “simplified” method in accordance with the SEC Staff Accounting Bulletin 107. The “simplified” method was used since the Company believes its historical data does not provide a reasonable basis upon which to estimate expected term and the Company does not have enough option exercise data from its grants issued to support its own estimate as a result of vesting terms and changes in the stock price. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. The following table provides the weighted average fair value of options granted to directors and employees and the related assumptions used in the Black-Scholes model: Year Ended October 31, 2018 October 31, 2017 Weighted average fair value of options granted $ 1.61 $ 6.36 Expected term 5.35-6.51 years 5.50-6.50 years Expected volatility 91.14%-100.34 % 107.07%-110.93 % Expected dividends 0 % 0 % Risk free interest rate 1.81%-3.16 % 1.26%-1.58 % Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the years ended October 31, 2018 and 2017 was approximately $3.7 million and $17.2 million, respectively. Included in compensation expense for the year ended October 31, 2018 is approximately $77,000 recognized as a result of the modification of certain option agreements associated with two Board members that decided not to run for re-election in March 2018. For the modified options, the vesting was accelerated and the expiration dates were changed to the earlier of the original expiration date or March 21, 2023. Included in fiscal 2017 compensation expense is $1.6 million recognized as a result of the modification of certain option agreements associated with the resignation of the Company’s Chief Executive Officer in July 2017. Pursuant to the separation agreement all the outstanding options vested immediately and the expiration date was extended until July 5, 2021. During the year ended October 31, 2018, 2,518,060 options were granted with a total grant date fair value of approximately $4.1 million. During the year ended October 31, 2017, 556,952 options were granted with a total grant date fair value of approximately $3.5 million. As of October 31, 2018, there was approximately $2.3 million of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 2.18 years. Shares Issued to Consultants During the year ended October 31, 2017, 165,907 shares of common stock valued at $1.4 million were issued to consultants for services. The common stock share values were based on the dates the shares vested. Employee Stock Purchase Plan The Advaxis, Inc. 2011 Employee Stock Purchase Plan (“2011 ESPP”) was approved by the Company’s stockholders in September 2011. The 2011 ESPP allowed employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2011 ESPP beginning December 30, 2011. 40,000 shares of the Company’s common stock were reserved for issuance under the 2011 ESPP. During the year ended October 31, 2017, 26,594 shares were issued under the 2011 ESPP and the Company recorded an expense of approximately $80,000. As of October 31, 2017, no shares of Company’s common stock remained available for issuance under the ESPP. 10,681 shares purchased under the 2011 ESPP during year ended October 31, 2017 were issued during the year ended October 31, 2018. The Advaxis, Inc. 2015 Employee Stock Purchase Plan (“2015 ESPP”) was approved by the Company’s shareholders on March 21, 2018. The 2015 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2015 ESPP beginning May 1, 2018. 1,000,000 shares of the Company’s Common stock are reserved for issuance under the 2015 ESPP. During the year ended October 31, 2018, 28,490 shares were issued under the ESPP and the Company recorded an expense of approximately $7,000. As of October 31, 2018, 971,510 shares of Company’s common stock remain available for issuance under the 2015 ESPP.

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	12 Months Ended
	Oct. 31, 2018
Collaboration And Licensing Agreements
Collaboration and Licensing Agreements	9. COLLABORATION AND LICENSING AGREEMENTS OS Therapies LLC On September 4, 2018, the Company granted a license to OS Therapies for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, OST, in collaboration with the Children’s Oncology Group, will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Pursuant to the agreement, the Company is to receive an upfront payment, reimbursement for product supply and other support, clinical, regulatory, and sales-based milestone payments, and royalties on future product sales. Amgen On August 1, 2016, the Company entered into a global agreement (the “Amgen Agreement”) with Amgen for the development and commercialization of the Company’s ADXS-NEO, a novel, preclinical investigational immunotherapy, using the Company’s proprietary Listeria monocytogenes attenuated bacterial vector which activates a patient’s immune system to respond against unique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor. Under the terms of the Amgen Agreement, Amgen received an exclusive worldwide license to develop and commercialize ADXS-NEO. On December 10, 2018, the Company received a written notice of termination from Amgen with respect to the Amgen Agreement. The termination is effective as of February 8, 2019. The Company is currently evaluating its options relating to its ADXS-NEO program. Pursuant to the terms of the Amgen Agreement, upon Amgen’s termination, the license to Amgen will terminate and the Company will regain worldwide rights for the development and commercialization of its ADXS-NEO program. In addition, Amgen will have certain obligations as set forth in the Amgen Agreement, including promptly deleting or destroying any materials related to the development or manufacturing of the ADXS-NEO program. Amgen had previously made an upfront payment to Advaxis of $40 million and purchased $25 million of Advaxis common stock. Amgen funded the clinical development and commercialization of ADXS-NEO and Advaxis retained manufacturing responsibilities. Advaxis and Amgen had collaborated through a joint steering committee for the development and commercialization of ADXS-NEO. Advaxis was eligible to receive future contingent payments based on development, regulatory and sales milestone payments of up to $475 million and high single digit to double digit royalty payments based on worldwide sales by Amgen. The Company identified the following performance obligations under the agreement: 1) the license, 2) the obligation to provide research activities, 3) the obligation to provide clinical supplies, 4) the obligation to perform regulatory functions and 5) the obligation to participate on a Joint Steering Committee. The Company considered the provisions of the multiple-element arrangement guidance in determining how to recognize the total consideration of the agreement. The Company determined that none of the deliverables have standalone value; all of these obligations will be delivered throughout the estimated period of performance and therefore are accounted for as a single unit of accounting. Accordingly, the Company recorded the $40 million upfront payment as deferred revenue on the balance sheet and will recognize revenue on a straight-line basis over the estimated period of performance. Changes in the estimated period of performance will be accounted for prospectively as a change in estimate. During the years ended October 31, 2018 and 2017, the Company recognized revenue from the Amgen Agreement of approximately $5.8 million and $11.8 million, respectively, related to amortization of the upfront fees. On December 10, 2018, the Company received a written notice of termination of the Amgen Agreement (see Note 9). In connection with the Amgen Agreement, Amgen purchased directly from Advaxis 3,047,446 shares of the Company’s common stock, at approximately $8.20 per share (representing a purchase at market using a 20 day VWAP methodology). The gross proceeds to Advaxis from the sale of the shares was approximately $25 million. The Company considered the provisions of the research and development and collaboration guidance in determining how to recognize the clinical development payments to be received from Amgen. The Company determined the clinical development payments should be accounted for within the scope of collaboration arrangement accounting guidance. As a result, the Company accounted for the clinical development payments as a reduction of research and development expenses in the statement of operations. During the years ended October 31, 2018 and 2017, the Company recorded reductions in research and development expenses of approximately $5.8 million and $7.5 million, respectively, pertaining to the reimbursement of clinical development payments. Especificos Stendhal SA de CV On February 3, 2016, the Company entered into a Co-Development and Commercialization Agreement (the “Stendhal Agreement”) with Especificos Stendhal SA de CV (“Stendhal”), for Advaxis’ lead Lm The Company considered the provisions of the research and development and collaboration guidance in determining how to recognize the Support Payments to be received from Stendhal. The Company determined the Stendhal Agreement should be accounted for within the scope of collaboration arrangement accounting guidance. As a result, the Company accounted for the support payments as a reduction of research and development expenses in the statement of operations. During the year ended October 31, 2017, the Company reached the annual project milestones and received a $3,000,000 Support Payment from Stendhal. In September 2018, the Company received a Notice of Arbitration from Stendhal relating to the Stendhal Agreement, see Note 10. Merck & Co., Inc. On August 22, 2014, the Company entered into a Clinical Trial Collaboration and Supply Agreement (the “Merck Agreement”) with Merck, pursuant to which the parties are collaborating on a Phase 1/2 dose-determination and safety trial. The Phase 1 portion of the trial evaluated the safety of our Lm Each party is responsible for their own internal costs and expenses to support the trial, while the Company will be responsible for all third party costs of conducting the trial. Merck is responsible for manufacturing and supplying the Merck Compound. The Company is responsible for manufacturing and supplying the Advaxis Compound. The Company is the sponsor of the trial and hold the IND related to the trial. All data and results generated under the trial (“Collaboration Data”) will be jointly owned by the parties, except that ownership of data and information generated from sample analysis to be performed by each party on its respective compound will be owned by the party conducting such testing. All rights to all inventions and discoveries, which claim or cover the combined use of the Advaxis Compound and the Merck Compound shall belong jointly to the parties. Inventions and discoveries relating solely to the Advaxis Compound, or a live attenuated bacterial vaccine, shall be the exclusive property of us. Inventions and discoveries relating solely to the Merck Compound, or a PD-1 antagonist, shall be the exclusive property of Merck. Enrollment for both phases of the clinical trial is complete. The Company anticipates providing an update on survival rates along with correlative biomarker work in the first quarter of 2019. During the years ended October 31, 2018 and 2017, the Company incurred approximately $2.4 million and $2.9 million, respectively, in expenses pertaining to the Merck agreement, and such expenses were a component of research and development expenses in the statement of operations. MedImmune/AstraZeneca On July 21, 2014, the Company entered into a Clinical Trial Collaboration Agreement (the “MedImmune Agreement”) with MedImmune, the global biologics research and development arm of AstraZeneca, pursuant to which the parties initiated a Phase 1/2 clinical trial in the United States to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with our investigational Lm -LLO cancer immunotherapy, axalimogene filolisbac, as a combination treatment for patients with advanced, recurrent or refractory cervical cancer and HPV-associated head and neck cancer. A joint steering committee, composed of equal representatives from both parties, is responsible for various matters associated with the collaboration, including protocol approval, as well as reviewing and monitoring the progress of the trial. In November 2018, the Company announced that it will not continue enrollment of this study. Subjects will enter a 3-year Lm surveillance period beginning at the completion of study treatment or at the time of study discontinuation. MedImmune is responsible for providing MEDI4736 at no cost, as well as costs related to the proprietary assays performed by MedImmune or a third party on behalf of MedImmune. The Company is the sponsor of the trial and is responsible for the submission of all regulatory filings to support the trial, the negotiation and execution of the clinical trial agreements associated with each trial site, and the packaging and labelling of the Advaxis and MedImmune product candidates used in the trial and the costs associated therewith. For a period beginning upon the completion of the trial and the receipt by MedImmune of the last final report for the trial and ending one hundred twenty (120) days thereafter (unless extended), MedImmune will be granted first right to negotiate in good faith in an attempt to enter into an agreement with us with respect to the development, regulatory approval and commercialization of axalimogene filolisbac and MEDI4736 to be used in combination with each other for the treatment or prevention of cancer. Neither party is obligated to enter into such an agreement. In the event the parties do not enter an agreement and the Company obtain regulatory approval for axalimogene filolisbac in combination with any PD-1 antibody or PD-L1 antibody, the Company shall pay MedImmune a royalty obligation and one-time payment. All intellectual property rights made, conceived or generated through the clinical trials that relate solely to a MedImmune development product shall be owned solely by MedImmune. All intellectual property rights made, conceived or generated through the clinical trials that relate solely to an Advaxis development product shall be owned solely by us. All intellectual property rights made, conceived or generated through the clinical trials that relate to the combination of one or more MedImmune development product and one or more Advaxis development product shall be jointly owned by both parties; provided, however that in the event the parties do not enter into a clinical development and commercialization agreement, the Company will not exploit, commercialize or license the joint inventions, except for the performance of its obligations under the MedImmune Agreement. MedImmune has the sole right to prosecute and enforce all patents and other intellectual property rights covering all joint inventions and all associated costs will be shared by the parties. The MedImmune Agreement shall remain in effect until the earlier of (i) permitted termination, (ii) the parties entering into a clinical development and commercialization agreement or expiration of the negotiation period (unless extended), except with respect to rights that survive termination. Either party may terminate the MedImmune Agreement upon thirty (30) days written notice upon material breach of the other party, unless the breach is cured in such period or reasonable actions to cure the breach are initiated and pursued (if the breach is not capable of being cured during the 30-day notice period). In addition, either party may terminate the MedImmune Agreement immediately if the party determines in good faith that the trials may unreasonably affect the safety of trial subjects. During the years ended October 31, 2018 and 2017, the Company incurred approximately $2.7 million and $2.8 million, respectively, in expenses pertaining to the MedImmune agreement, and such expenses were a component of research and development expenses in the statement of operations. Aratana Therapeutics On March 19, 2014, the Company and Aratana entered into a definitive Exclusive License Agreement (the “Aratana Agreement”). Pursuant to the Agreement, Advaxis granted Aratana an exclusive, worldwide, royalty-bearing, license, with the right to sublicense, certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted for treatment of osteosarcoma and other cancer indications in animals. Under the terms of the Aratana Agreement, Aratana paid an upfront payment to the Company, of $1 million. As this license has stand-alone value to Aratana (who has the ability to sublicense) and was delivered to Aratana, upon execution of the Aratana Agreement, the Company recorded the $1 million payment as licensing revenue during the year ended October 31, 2014. Aratana will also pay the Company up to an additional $36.5 million based on the achievement of certain milestones with respect to the advancement of products pursuant to the terms of the Aratana Agreement. In addition, Aratana may pay the Company an additional $15 million in cumulative sales milestones pursuant to the terms of the Aratana Agreement. Advaxis (i) issued and sold 306,122 shares of Advaxis’ common stock to Aratana at a price of $4.90 per share, which was equal to the closing price of the common stock on the NASDAQ Capital Market on March 19, 2014, and (ii) issued a ten-year warrant to Aratana giving Aratana the right to purchase up to 153,061 additional shares of Advaxis’ common stock at an exercise price of $4.90 per share. In connection with the sale of the common stock and warrants, Advaxis received aggregate net proceeds of $1,500,000. Aratana exercised all of its 153,061 warrants. As a result, no warrants remain outstanding under this agreement. During the year ended October 31, 2018, the USDA’s Center for Veterinary Biologics granted Aratana conditional approval for its canine osteosarcoma vaccine using Advaxis’ technology. For the year ended October 31, 2018, Advaxis recognized royalty revenue totaling approximately $5,000 from Aratana’s sales of the canine osteosarcoma vaccine. Global BioPharma Inc. On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). GBP is planning to conduct a randomized Phase 2, open-label, controlled trial in HPV-associated NSCLC in patients following first-line induction chemotherapy. GBP has obtained Taiwanese regulatory approval for this trial and plans to initiate this trial in 2019. This trial will be fully funded exclusively by GBP. GBP will continue to explore the use of our lead product candidate in several other indications including head and neck, and anal cancer. GBP also plans to conduct registration trials with axalimogene filolisbac for the treatment of advanced cervical cancer. GBP will pay Advaxis event-based financial milestones, an annual license fee, and annual net sales royalty payments in the high single to double digits. In addition, as an upfront payment, GBP made an investment in Advaxis of $400,000 by purchasing from the Company 108,724 shares of its common stock at a price of $3.68 per share, GBP also received 100,000 warrants at an exercise price of $5.52 which expire in December 2018. GBP exercised all of its 100,000 warrants. As a result no warrants remain outstanding under this agreement. GBP will be responsible for all clinical development and commercialization costs in the GBP territory. GBP will also reimburse Advaxis $2.25 million toward AIM2CERV. GBP is committed to establishing manufacturing capabilities for its own. Under the terms of the agreement, the Company will exclusively license the rights of axalimogene filolisbac to GBP for the Asia, Africa, and former USSR territory, exclusive of India and certain other countries, for all HPV-associated indications. Advaxis will retain exclusive rights to axalimogene filolisbac for the rest of the world. During each of the years ended October 31, 2018 and 2017, the Company recognized revenue of $250,000 for annual license fees.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Oct. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. COMMITMENTS AND CONTINGENCIES Legal Proceedings Knoll On August 21, 2015, Knoll Capital Management L.P. (“KCM”) filed a complaint against the Company in the Delaware Court of Chancery. The complaint alleged the existence of an oral agreement for the purchase by Knoll from the Company of 1,666,666.67 shares of Company stock at a price of $3.00 per share. KCM alleged that the Company breached this alleged agreement and sought specific performance or, alternatively, money damages for breach of contract. KCM served the Company with the complaint on August 31, 2015, and then served an amended complaint on October 16, 2015. The Company moved to dismiss the amended complaint on October 26, 2015 and that motion was denied on January 29, 2016. The Company filed an answer to the amended complaint on February 12, 2016. In lieu of continuing to unnecessarily incur litigation expenses, on April 27, 2017, the Company settled the matter for a non-material amount, predominately reimbursed by the Company’s insurance, and the parties entered into a definitive confidential settlement agreement. The Company expressly denies any admission or wrongdoing and the settlement was entered into solely for the purpose of avoiding the burden, inconvenience, and expense of further litigation. On May 11, 2017, following resolution of the matter by the parties, the Court granted a Stipulation of Dismissal with Prejudice. Bono On August 20, 2015, a derivative complaint was filed by a purported Company stockholder in the United States District Court for the District of New Jersey styled David Bono v. O’Connor, et al., Case No. 3:15-CV-006326-FLW-DEA (D.N.J. Aug. 20, 2015) (the “Bono Action”). The complaint was based on general allegations related to certain stock options granted to the individual defendants and generally alleged counts for breaches of fiduciary duty and unjust enrichment. The complaint also alleged additional claims for violation of Section 14(a) of the Securities Exchange Act of 1934 and for waste of corporate assets. The complaint sought damages and costs of an unspecified amount, disgorgement of compensation obtained by the individual defendants, and injunctive relief. Defendants filed a motion to dismiss the Bono Action. On May 23, 2016, the Court issued an opinion and order granting in part and denying in part defendants’ motion to dismiss. On October 5, 2016, the Court denied plaintiff’s motion for reconsideration of its May 23 order. On April 13, 2017, the parties advised the Court that they had reached a tentative agreement in principle to settle the action, subject to negotiating an award of attorneys’ fees and expenses to plaintiff’s counsel and a stipulation of settlement, and, ultimately Court approval. The parties subsequently executed the stipulation of settlement on October 2, 2017. The Court entered an order preliminarily approving the settlement on November 7, 2017. The final fairness hearing was held January 29, 2018, and the Order and Final Judgment approving the settlement and dismissing the action with prejudice was entered on January 29, 2018. This matter is now concluded. Stendhal On September 19, 2018, Stendhal filed a Demand for Arbitration before the International Centre for Dispute Resolution (Case No. 01-18-0003-5013) relating to the Stendhal Agreement. In the demand, Stendhal alleged that (i) the Company breached the Stendhal Agreement when it made certain statements regarding its AIM2CERV program, (ii) that Stendhal was subsequently entitled to terminate the Agreement for cause, which it did so at the time and (iii) that the Company owes Stendhal damages pursuant to the terms of the Stendhal Agreement. Stendhal is seeking to recover $3 million paid to the Company in 2017 as support payments for the AIM2CERV clinical trial along with approximately $0.3 million in expenses incurred. Stendhal is also seeking fees associated with the arbitration and interest. The Company has answered Stendhal’s Demand for Arbitration, and denied that it breached the Stendhal Agreement. The Company also alleges that Stendhal breached its obligations to the Company by, among other things, failing to make support payments that became due in 2018 and that Stendhal therefore owes the Company $3 million. While, the arbitration is still in its early stages. the Company intends to continue to vigorously defend itself against this matter. At this time, we are unable to predict the likelihood of an unfavorable outcome. Corporate Office & Manufacturing Facility Lease The Company leases its corporate office and manufacturing facility under an operating lease expiring in November 2025. Future minimum payments under the Company’s operating leases are as follows (in thousands): Year ended October 31, 2019 $ 1,107 2020 1,233 2021 1,318 2022 1,369 2023 1,395 Thereafter 2,983 Total $ 9,405 Rent expense for each of the years ended October 31, 2018 and 2017 was approximately $1.2 million.

Income Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	11. INCOME TAXES: The income tax provision (benefit) consists of the following (in thousands): October 31, 2018 October 31, 2017 Federal Current $ - $ - Deferred 22,325 (34,296 ) State and Local Current - (4,453 ) Deferred (5,449 ) (1,124 ) Change in valuation allowance (16,876 ) 35,420 Income tax provision (benefit) $ - $ (4,453 ) The Company has U.S. federal net operating loss carryovers (“NOLs”) of approximately $265.8 million and $187.4 million at October 31, 2018 and 2017 respectively, available to offset taxable income which expire beginning in 2023. If not used, these NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations. During the years ended October 31, 2018 and 2017, the Company performed a detailed analysis of any historical and/or current Section 382 ownership changes that may limit the utilization of the net operating loss carryovers. From the entire federal NOL of $290.6 million as of October 31, 2018, approximately $265.8 million is available for immediate use based on Internal Revenue Code Section 382 analysis. The NOL and the deferred tax asset table below does not include approximately $24.8 million of NOL’s that may expire unused. The Company also has New Jersey State Net Operating Loss carryovers of approximately $129.2 million as of October 31, 2018 available to offset future taxable income through 2038. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon future generation for taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act made broad and significant changes to the U.S. tax code including, but not limited to, a change in the federal rate from 34% to 21%. As a result of the enactment of the legislation, the Company recorded a one-time reduction to its deferred tax assets of approximately $34.4 million, which was offset by a reduction in the valuation allowance. When a U.S. federal tax rate change occurs during a fiscal year, taxpayers are required to compute a weighted daily average rate for the fiscal year of enactment. As a result of the Tax Act, Advaxis has calculated a blended U.S. federal statutory corporate income tax rate of approximately 23% for the year ended October 31, 2018 and applied this rate in computing the income tax provision for year ending October 31, 2018. The blended U.S. federal statutory corporate income tax rate of 23% is the weighted daily average rate between the pre-enactment U.S. federal statutory tax rate of 34% applicable to the Company’s 2018 fiscal year prior to the Effective Date and the post-enactment U.S. federal statutory tax rate of 21% applicable to the 2018 fiscal year thereafter. Advaxis expects the U.S. federal statutory rate to be 21% for fiscal years beginning after October 31, 2018. The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. If applicable, interest costs related to the unrecognized tax benefits are required to be calculated and would be classified as other expense in the statement of operations. Penalties would be recognized as a component of general and administrative expenses in the statement of operations. No interest or penalties on unpaid tax were recorded during the years ended October 31, 2018 and 2017, respectively. As of October 31, 2018 and 2017, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company files tax returns in the U.S. federal and state jurisdictions and is subject to examination by tax authorities beginning with the year ended October 31, 2014. The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following (in thousands): Years Ended October 31, 2018 October 31, 2017 Deferred Tax Assets Net operating loss carryovers $ 65,002 $ 66,681 Stock-based compensation 12,081 21,921 Research and development credits 6,843 7,293 Deferred revenue 5,247 9,775 Other deferred tax assets 587 1,515 Total deferred tax assets $ 89,760 $ 107,185 Valuation allowance (87,862 ) (104,738 ) Deferred tax asset, net of valuation allowance $ 1,898 $ 2,447 Deferred Tax Liabilities Other deferred tax liabilities $ (1,898 ) $ (2,447 ) Total deferred tax liabilities $ (1,898 ) $ (2,447 ) Net deferred tax asset (liability) $ - $ - The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows: Years Ended October 31, 2018 October 31, 2017 US Federal statutory rate 23.17 % 34.00 % State income tax, net of federal benefit 8.19 1.15 Permanent differences 1.22 (2.30 ) Research and development credits (0.38 ) 2.36 Income tax benefit from sale of New Jersey NOL carryovers - 4.55 Change in valuation allowance 25.37 (36.20 ) Tax Cuts and Jobs Act (53.93 ) - Other (3.64 ) 0.99 Income tax (provision) benefit 0.00 % 4.55 % Sale of Net Operating Losses (NOLs) The Company was eligible to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In January 2018, the Company received a net cash amount of approximately $4.5 million from the sale of its state NOLs and research and development tax credits for the year ended October 31, 2016. Following the receipt of the NOL and research and development tax credit for the year ending October 31, 2016, the Company reached the limit under the NJ NOL program.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Oct. 31, 2018
Equity [Abstract]
Shareholders' Equity	12. SHAREHOLDERS’ EQUITY: At-the-Market Transactions During January 2018, the Company sold 881,629 shares of its common stock at-the-market transactions resulting in net proceeds of approximately $2.7 million. Additionally, in May 2017 and June 2017, the Company sold a total of 92,145 shares of its common stock at-the-market transactions resulting in net proceeds of approximately $0.7 million. Public Offerings During February 2018, the Company closed on an underwritten public offering of 10,000,000 shares of the Company’s common stock in a public offering at $2.00 per share, for total gross proceeds of $20 million. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $18.4 million. In addition, pursuant to the underwriting agreement, the Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 807,697 shares of common stock. The sale of the Offered Shares was registered pursuant to a Registration Statement (No. 333-216008) on Form S-3, as amended, which was filed by the Company with the Securities and Exchange Commission on March 17, 2017 and declared effective on March 20, 2017. In September 2018, the Company closed on an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock at a public offering price of $1.20, for gross proceeds of $20 million. Each share of common stock was sold together in a fixed combination with a warrant to purchase 0.85 shares of common stock. The warrants are exercisable immediately, expire six years from the date of issuance and have an exercise price of $1.50 per share, subject to anti-dilution adjustments (see Note 7). After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $18.2 million. The shares of common stock were sold pursuant to an effective shelf registration statement on Form S-3 (No. 333- 226988) filed with the Securities and Exchange Commission on August 23, 2018 and declared effective on August 30, 2018.

Fair Value

Fair Value	12 Months Ended
	Oct. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value	13. FAIR VALUE The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. ● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities. ● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities. The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2018. The Company had no assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2017: October 31, 2018 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $1.50 through September 2024 - - $ 6,517 $ 6,517 The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities: October 31, 2018 Beginning balance $ - Issuance of warrants 9,917 Change in fair value (3,400 ) Ending Balance 6,517

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Oct. 31, 2018
Compensation Related Costs [Abstract]
Employee Benefit Plan	14. EMPLOYEE BENEFIT PLAN The Company sponsors a 401(k) Plan. Employees become eligible for participation upon the start of employment. Participants may elect to have a portion of their salary deferred and contributed to the 401(k) Plan up to the limit allowed under the Internal Revenue Code. The Company makes a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year. The Company made matching contributions which amounted to approximately $0.4 million and $0.4 million for the years ended October 31, 2018 and 2017, respectively. These amounts were charged to the statement of operations. The employer contributions vest immediately.

Subsequent Events

Subsequent Events	12 Months Ended
	Oct. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	15. SUBSEQUENT EVENTS Option Grants On November 5, 2018, the Company granted to executives and non-executive directors 720,000 and 130,000 options, respectively, with an exercise price of $0.54. The options vest annually in three equal installments beginning on the first anniversaries of the grant date. Amgen Agreement Termination On December 10, 2018, the Company received a written notice of termination from Amgen with respect to the Amgen Agreement. The termination is effective as of February 8, 2019. The Company’s ADXS-NEO study is currently enrolling patients and the Company will evaluate whether to re-partner the ADXS-NEO program. Pursuant to the terms of the Amgen Agreement, upon Amgen’s termination, the license to Amgen will terminate and the Company will regain worldwide rights for the development and commercialization of its ADXS-NEO program. In addition, Amgen will have certain obligations as set forth in the Amgen Agreement, including promptly deleting or destroying any materials related to the development or manufacturing of the ADXS-NEO program. During the fiscal years ended October 31, 2018 (unaudited) and 2017, the Company recorded reimbursements of approximately $5.8 million and $7.5 million, respectively, relating to the Amgen Agreement

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2018
Accounting Policies [Abstract]
Estimates	Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used when accounting for such items as the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), deferred expenses and deferred revenue, the fair value of options, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may or may not differ from estimates.
Reclassification	Reclassification Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.
Collaboration Agreements	Collaboration Agreements The Company evaluates whether an arrangement is a collaborative arrangement under the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements, at its inception based on the facts and circumstances specific to the arrangement. The Company also reevaluates whether an arrangement qualifies or continues to qualify as a collaborative arrangement whenever there is a change in either the roles of the participants or the participants’ exposure to significant risks and rewards dependent on the ultimate commercial success of the endeavor. For those collaborative arrangements where it is determined that the Company is the principal participant, costs incurred and revenue generated from third parties are recorded on a gross basis in the financial statements. From time to time, the Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of products and product candidates. These collaborations generally provide for non-refundable, upfront license fees, research and development and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. The Company’s collaboration agreements with third parties are performed on a ‘‘best efforts’’ basis with no guarantee of either technological or commercial success.
Revenue Recognition	Revenue Recognition The Company has derived the majority of its revenue from patent licensing and research and development services associated with patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured. Revenue associated with nonrefundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected period of performance. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestones as revenue on a straight-line basis over the remaining expected performance period under the arrangement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s statements of operations. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, and the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received. Deferred revenue represents the portion of payments received for which the earnings process has not been completed. Deferred revenue expected to be recognized within the next 12 months is classified as a current liability. An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $43.8 million is subject to credit risk at October 31, 2018. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
Restricted Cash and Letter of Credit	Restricted Cash and Letter of Credit During July 2017 and January 2018, the Company established two letters of credit with a financial institution as security for the purchase of custom equipment and as security for application fees associated with the Company’s Marketing Authorization Application (“MAA”) in Europe. The letters of credit are collateralized by cash which is unavailable for withdrawal or for usage for general obligations. No amount is outstanding under either letter of credit as of October 31, 2018.
Investments	Investments Investment securities consist of certificates of deposit, domestic governmental agency loans, and U.S. treasury notes. The Company classifies these securities as held-to-maturity. Held-to-maturity securities are those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method. A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in Other Income (Expense), net. The Company did not recognize any impairment charges during the years ended October 31, 2018 or 2017. Interest income is recognized when earned.
Deferred Expenses	Deferred Expenses Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operations as the research and development activity is performed.
Property and Equipment	Property and Equipment Property and equipment is stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three to ten years. When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.
Intangible Assets	Intangible Assets Intangible assets are recorded at cost and include patents and patent application costs, licenses and software. Intangible assets are amortized on a straight-line basis over their estimated useful lives ranging from 3 to 20 years. Patent application costs are written-off if the application is rejected, withdrawn or abandoned.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The company reviews its long-lived assets, including property and equipment and intangible assets, for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, an impairment loss is recognized in the Statement of Operations based on the excess of the carrying amount over the fair value of the asset.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. In the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share. As of October 31, 2018 2017 Warrants 14,169,542 3,092,935 Stock options 4,951,049 3,893,558 Restricted stock units 489,270 1,363,119 Total 19,609,861 8,349,612
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs.
Stock Based Compensation	Stock Based Compensation The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants. The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its common stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants. The Company accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants.
Treasury Stock	Treasury Stock The Company accounts for repurchases of common stock and shares withheld in lieu of taxes when restricted stock vests using the cost method with common stock in treasury classified in the balance sheet as a reduction in shareholders’ equity.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments, including cash and cash equivalents, restricted cash and accounts payable approximated fair value as of the balance sheet date presented, due to their short maturities.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Monte Carlo valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.
Recent Accounting Standards	Recent Accounting Standards In February 2016, the Financial Accounting Standards Board, or FASB, issued ASU, No. 2016-02, Leases (Topic 842), which establishes a comprehensive new lease accounting model. The new standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than 12 months. The new standard is effective for fiscal years and interim periods beginning after December 15, 2018, with early adoption permitted. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements, an update which provides another transition method, in addition to the existing modified retrospective transition method, by allowing entities to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new standard changes the presentation of restricted cash and cash equivalents on the statement of cash flows. Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The amendments in this Update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of businesses. The amendments in this Update provide a screen to determine when a set is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. This Update is the final version of Proposed ASU 2015-330 Business Combinations (Topic 805) – Clarifying the Definition of a Business, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This Update is the final version of Proposed ASU 2016-360—Compensation—Stock Compensation (Topic 718)—Scope of Modification Accounting, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”), which expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted, but no earlier than our adoption of ASC 606. This ASU is not expected to have a material impact on the Company’s financial statements.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (“ASU 2016-08”); ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”); ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”); ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers (“ASU 2016-20”); Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842) (“ASU 2017-13”); and ASU 2017-14, Income Statement—Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) (“ASU 2017-14”). The Company must adopt ASU 2016-08, ASU 2016-10, ASU 2016-12, ASU 2016-20, ASU 2017-13 and ASU 2017-14 with ASU 2014-09 (collectively, the “new revenue standards”). The new revenue standards may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company has completed its assessment of the impact that the standard will have on revenue recognition. The Company has reviewed contracts for all material revenue streams and assessed potential impacts on the Company’s financial statements, results of operations, cash flows, disclosures, and internal controls over financial reporting. The Company currently recognizes most of its revenue over time. Management has determined that this will remain materially consistent upon adoption of the new standard and no adjustment to the Company’s financial position, results of operations, or cash flows will be necessary upon adoption. Additionally, the Company will make additional disclosures related to the revenues arising from contracts with customers as required by the new standard. The Company has adopted this guidance effective November 1, 2019 using the modified retrospective approach. In August 2014, the FASB issued ASU No. 2014-15, Disclosures of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, ending after December 15, 2016. The Company adopted this standard effective for the year ending October 31, 2017. There was no impact on the Company’s financial statements. In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Equity from Liabilities (Topic 480) and Derivatives and Hedging (Topic 815) (“ASU 2017-11”), which addresses the complexity of accounting for certain financial instruments with down round features and finalizes pending guidance related to mandatorily redeemable noncontrolling interests. Under ASU 2017-11, when determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU 2017-11 becomes effective for annual reporting periods beginning after December 15, 2018, including interim periods thereafter; early adoption is permitted, including adoption in an interim period. The Company early adopted this standard utilizing the modified retrospective method, which is defined in ASU 2017-11 as, “retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the first fiscal year and interim period(s).” Since the Company didn’t have any financial instruments with a down round feature as of November 1, 2017, the beginning of the fiscal year of adoption, the adoption of this standard did not have an impact on the Company’s financial statements. In November 2018, the FASB issued ASU No. 2018-18, “Collaborative Arrangements (Topic 808)—Clarifying the Interaction between Topic 808 and Topic 606” (“ASU 2018-18”). The amendments in ASU 2018-18 make targeted improvements to generally accepted accounting principles (GAAP) for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in Topic 606 should be applied, including recognition, measurement, presentation, and disclosure requirements. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606. ASU 2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in this Update should be applied retrospectively to the date of initial application of Topic 606. The Company has adopted this guidance effective November 1, 2018 using the modified retrospective approach. There was no impact on the Company’s financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Oct. 31, 2018
Accounting Policies [Abstract]
Schedule of Common Stock Excluded from Diluted Net Loss Per Share	The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share. As of October 31, 2018 2017 Warrants 14,169,542 3,092,935 Stock options 4,951,049 3,893,558 Restricted stock units 489,270 1,363,119 Total 19,609,861 8,349,612

Investments (Tables)

Investments (Tables)	12 Months Ended
	Oct. 31, 2018
Schedule of Investments [Abstract]
Schedule of Investment Securities at Amortized	The following table summarizes the Company’s investment securities at amortized cost as of October 31, 2017 (in thousands): October 31, 2017 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value Short-term investments: Certificates of Deposit $ 11,391 $ - $ - $ 11,391 Domestic Governmental Agency Loans 500 - - 500 U.S Treasury Notes 34,507 - 25 34,482 Total short-term investment securities $ 46,398 $ - $ 25 $ 46,373

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Oct. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following (in thousands): October 31, 2018 2017 Leasehold improvements $ 2,321 $ 2,168 Laboratory equipment 5,510 4,381 Furniture and fixtures 746 729 Computer equipment 409 395 Construction in progress 17 645 Total property and equipment 9,003 8,318 Accumulated depreciation and amortization (2,319 ) (1,207 ) Net property and equipment $ 6,684 $ 7,111

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Oct. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets consist of the following (in thousands): October 31, 2018 2017 Patents $ 5,970 $ 5,727 License 777 777 Software 117 109 Total intangibles 6,864 6,613 Accumulated amortization (2,026 ) (1,756 ) Net intangible assets $ 4,838 $ 4,857
Schedule of Amortization Expense	At October 31, 2018, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands): 2019 $ 392 2020 376 2021 356 2022 356 2023 356 Thereafter 3,002 Total $ 4,838

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Oct. 31, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	The following table represents the major components of accrued expenses (in thousands): October 31, 2018 2017 Salaries and other compensation $ 2,035 $ 2,653 Vendors 3,660 2,812 Professional fees 490 3,235 Total accrued expenses $ 6,185 $ 8,700

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants and Warrant Liability (Tables)	12 Months Ended
	Oct. 31, 2018
Common Stock Purchase Warrants And Warrant Liability
Schedule of Warrants Activity	A summary of warrant activity was as follows (In thousands, except share and per share data): Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding and exercisable warrants at October 31, 2016 3,110,575 $ 5.04 1.91 $ 9,558 Exercised (225 ) 5.00 Expired (17,955 ) 11.43 Outstanding and exercisable warrants at October 31, 2017 3,092,395 $ 5.00 .92 $ - Issued 14,166,666 1.50 Expired (3,089,519 ) 5.00 Outstanding and exercisable warrants at October 31, 2018 14,169,542 $ 1.50 5.87 $ -
Schedule of Assumptions Used in Warrant Liability	In measuring the warrant liability at October 31, 2018, the Company used the following inputs in its Monte Carlo Model: October 31 ,2018 Exercise Price $ 1.50 Stock Price $ 0.56 Expected Term 5.87 years Volatility % 97.47 % Risk Free Rate 3.03 %

Share Based Compensation (Table

Share Based Compensation (Tables)	12 Months Ended
	Oct. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Share Based Compensation Expense	The following table summarizes share-based compensation expense included in the statement of operations by expense category for the years ended October 31, 2018 and 2017 (in thousands): Year Ended October 31, 2018 2017 Research and development $ 2,836 $ 5,648 General and administrative 4,147 22,188 Total $ 6,983 $ 27,836
Summary of RSU Activity and Related Information	A summary of the Company’s RSU activity and related information for the year ended October 31, 2018 and 2017 is as follows: Number of RSU’s Weighted-Average Grant Date Fair Value Balance at October 31, 2016: 719,448 $ 10.77 Granted 1,632,134 7.90 Vested (877,383 ) 9.15 Cancelled (111,080 ) 8.74 Balance at October 31, 2017 1,363,119 $ 8.54 Granted 409,950 1.97 Vested (808,097 ) 7.71 Cancelled (475,702 ) 8.23 Balance at October 31, 2018 489,270 $ 4.69
Summary of Changes in Stock Option Plan	A summary of changes in the stock option plan for the years ended October 31, 2018 and 2017 is as follows (In thousands, except share and per share data): Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding as of October 31, 2016 3,351,795 $ 13.31 7.82 $ 62 Granted 556,952 7.71 Cancelled or expired (15,189 ) 14.07 Outstanding as of October 31, 2017 3,893,558 $ 12.51 5.72 $ - Granted 2,518,060 2.06 Cancelled or expired (1,460,569 ) 9.14 Outstanding as of October 31, 2018 4,951,049 $ 8.19 6.56 $ - Vested and exercisable at October 31, 2018 2,827,171 $ 8.19 4.38 $ -
Summary of Outstanding and Exercisable Options	The following table summarizes information about the outstanding and exercisable options at October 31, 2018: Options Outstanding Options Exercisable Weighted Weighted Weighted Weighted Average Average Average Average Exercise Number Remaining Exercise Intrinsic Number Remaining Exercise Intrinsic Price Range Outstanding Contractual Price Value Exercisable Contractual Price Value $ 0.60 - $4.99 2,037,108 9.53 $ 1.97 $ - 165,834 7.27 $ 3.22 $ - $ 5.00 - $9.99 526,029 5.20 $ 7.98 $ - 393,424 4.37 $ 8.07 $ - $ 10.00 - $14.99 2,199,592 4.42 $ 13.14 $ - 2,079,593 4.27 $ 13.16 $ - $ 15.00 - $21.25 188,320 3.07 $ 18.12 $ - 188,320 3.07 $ 18.12 $ -
Summary of Fair Value of Stock Options Granted of BSM	The following table provides the weighted average fair value of options granted to directors and employees and the related assumptions used in the Black-Scholes model: Year Ended October 31, 2018 October 31, 2017 Weighted average fair value of options granted $ 1.61 $ 6.36 Expected term 5.35-6.51 years 5.50-6.50 years Expected volatility 91.14%-100.34 % 107.07%-110.93 % Expected dividends 0 % 0 % Risk free interest rate 1.81%-3.16 % 1.26%-1.58 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Oct. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Summary of Future Minimum Payments of Operating Leases	Future minimum payments under the Company’s operating leases are as follows (in thousands): Year ended October 31, 2019 $ 1,107 2020 1,233 2021 1,318 2022 1,369 2023 1,395 Thereafter 2,983 Total $ 9,405

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2018
Income Tax Disclosure [Abstract]
Components of Income Tax Provision (Benefit)	The income tax provision (benefit) consists of the following (in thousands): October 31, 2018 October 31, 2017 Federal Current $ - $ - Deferred 22,325 (34,296 ) State and Local Current - (4,453 ) Deferred (5,449 ) (1,124 ) Change in valuation allowance (16,876 ) 35,420 Income tax provision (benefit) $ - $ (4,453 )
Schedule of Deferred Tax Assets (Liabilities)	The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following (in thousands): Years Ended October 31, 2018 October 31, 2017 Deferred Tax Assets Net operating loss carryovers $ 65,002 $ 66,681 Stock-based compensation 12,081 21,921 Research and development credits 6,843 7,293 Deferred revenue 5,247 9,775 Other deferred tax assets 587 1,515 Total deferred tax assets $ 89,760 $ 107,185 Valuation allowance (87,862 ) (104,738 ) Deferred tax asset, net of valuation allowance $ 1,898 $ 2,447 Deferred Tax Liabilities Other deferred tax liabilities $ (1,898 ) $ (2,447 ) Total deferred tax liabilities $ (1,898 ) $ (2,447 ) Net deferred tax asset (liability) $ - $ -
Reconciliation Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit	The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows: Years Ended October 31, 2018 October 31, 2017 US Federal statutory rate 23.17 % 34.00 % State income tax, net of federal benefit 8.19 1.15 Permanent differences 1.22 (2.30 ) Research and development credits (0.38 ) 2.36 Income tax benefit from sale of New Jersey NOL carryovers - 4.55 Change in valuation allowance 25.37 (36.20 ) Tax Cuts and Jobs Act (53.93 ) - Other (3.64 ) 0.99 Income tax (provision) benefit 0.00 % 4.55 %

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Oct. 31, 2018
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The Company had no assets and liabilities carried at fair value measured on a recurring basis as of October 31, 2017: October 31, 2018 Level 1 Level 2 Level 3 Total Common stock warrant liability, warrants exercisable at $1.50 through September 2024 - - $ 6,517 $ 6,517
Schedule of Changes in the Fair Value of Warrant Liabilities	The following table sets forth a summary of the changes in the fair value of the Company’s warrant liabilities: October 31, 2018 Beginning balance $ - Issuance of warrants 9,917 Change in fair value (3,400 ) Ending Balance 6,517

Nature of Operations and Basi_2

Nature of Operations and Basis of Presentation (Details Narrative) $ in Thousands	12 Months Ended
	Oct. 31, 2018USD ($)
Cash, restricted cash, cash equivalents	$ 45,100
October 2013 Through October 2018 [Member]
Proceeds from public offering	265,000
December 31, 2018 [Member]
Cash, restricted cash, cash equivalents	$ 36,100

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) $ in Thousands	12 Months Ended
	Oct. 31, 2018USD ($)
Concentration of credit risk	$ 43,800
Lease term	12 months
Minimum [Member]
Estimated useful lives of property and equipment	3 years
Estimated useful life of intangible assets	3 years
Maximum [Member]
Estimated useful lives of property and equipment	10 years
Estimated useful life of intangible assets	20 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Common Stock Excluded from Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Number of common stock excluded from diluted net loss per share	19,609,861	8,349,612
Warrants [Member]
Number of common stock excluded from diluted net loss per share	14,169,542	3,092,935
Stock Options [Member]
Number of common stock excluded from diluted net loss per share	4,951,049	3,893,558
Restricted Stock Units [Member]
Number of common stock excluded from diluted net loss per share	489,270	1,363,119

Investments (Details Narrative)

Investments (Details Narrative)	12 Months Ended
	Oct. 31, 2018
Schedule of Investments [Abstract]
Investments maturity description	All of the Company's short-term investment securities have matured.

Investments - Schedule of Inves

Investments - Schedule of Investment Securities at Amortized (Details) $ in Thousands	12 Months Ended
	Oct. 31, 2017USD ($)
Amortized Cost, as Adjusted	$ 46,398
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses	25
Estimated Fair Value	46,373
Certificates of Deposit [Member]
Amortized Cost, as Adjusted	11,391
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Estimated Fair Value	11,391
Domestic Governmental Agency Loans [Member]
Amortized Cost, as Adjusted	500
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Estimated Fair Value	500
U.S Treasury Notes [Member]
Amortized Cost, as Adjusted	34,507
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses	25
Estimated Fair Value	$ 34,482

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,113	$ 791
Laboratory equipment, disposed	$ 614	$ 3

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Oct. 31, 2018	Oct. 31, 2017
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,321	$ 2,168
Laboratory equipment	5,510	4,381
Furniture and fixtures	746	729
Computer equipment	409	395
Construction in progress	17	645
Total property and equipment	9,003	8,318
Accumulated depreciation and amortization	(2,319)	(1,207)
Net property and equipment	$ 6,684	$ 7,111

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived patents expirations year	The expirations of the existing patents range from 2018 to 2038
Book value patent applications, net	$ 1,047	$ 315
Intangible asset amortization expense	$ 388	$ 330

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	Oct. 31, 2018	Oct. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 5,970	$ 5,727
License	777	777
Software	117	109
Total intangibles	6,864	6,613
Accumulated amortization	(2,026)	(1,756)
Net intangible assets	$ 4,838	$ 4,857

Intangible Assets - Schedule of

Intangible Assets - Schedule of Amortization Expense (Details) $ in Thousands	Oct. 31, 2018USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,019	$ 392
2,020	376
2,021	356
2,022	356
2,023	356
Thereafter	3,002
Total	$ 4,838

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Oct. 31, 2018	Oct. 31, 2017
Payables and Accruals [Abstract]
Salaries and other compensation	$ 2,035	$ 2,653
Vendors	3,660	2,812
Professional fees	490	3,235
Total accrued expenses	$ 6,185	$ 8,700

Common Stock Purchase Warrant_3

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Sep. 11, 2018	Oct. 31, 2018	Oct. 31, 2017
Number of warrants issued		2,876
Warrants issued		14,169,542	3,092,395
Exercise price of warrants		$ 1.50
Fair value of the warrant liability		$ 6,500	$ 0
Change in fair value of warrant liability		$ 3,400	$ 20
Warrant Liability [Member]
Number of warrants issued		14,166,666
Warrants issued		14,169,542
Exercise price of warrants		$ 1.50
Warrant term		6 years
Number of warrant issued, value	$ 9,900
Exercise price	$ 0.85	$ 1.50
Stock price	$ 1.50	$ 0.56
Expected term	6 years	5 years 10 months 14 days
Volatility percentage	99.21%	97.47%
Risk free interest rate	2.91%	3.03%
Fair value of the warrant liability		$ (3,400)

Common Stock Purchase Warrant_4

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Common Stock Purchase Warrants And Warrant Liability
Number of Warrants, Outstanding, Beginning balance	3,092,395	3,110,575
Number of Warrants, Issued	14,166,666
Number of Warrants, Exercised		(225)
Number of Warrants, Expired	(3,089,519)	(17,955)
Number of Warrants, Outstanding, Ending balance	14,169,542	3,092,395
Weighted-Average Exercise Price, Outstanding, Beginning	$ 5	$ 5.04
Weighted-Average Exercise Price, Issued	1.50
Weighted-Average Exercise Price, Exercised		5
Weighted-Average Exercise Price, Expired	5	11.43
Weighted-Average Exercise Price, Outstanding, Ending	$ 1.50	$ 5
Weighted Average Remaining Contractual Life In Years, Beginning	11 months 1 day	1 year 10 months 28 days
Weighted Average Remaining Contractual Life In Years, Ending	5 years 10 months 14 days	11 months 1 day
Aggregate Intrinsic Value, Beginning		$ 9,558
Aggregate Intrinsic Value, Ending

Common Stock Purchase Warrant_5

Common Stock Purchase Warrants and Warrant Liability - Schedule of Assumptions Used in Warrant Liability (Details) - Warrant Liability [Member] - $ / shares	Sep. 11, 2018	Oct. 31, 2018
Exercise Price	$ 0.85	$ 1.50
Stock Price	$ 1.50	$ 0.56
Expected Term	6 years	5 years 10 months 14 days
Volatility %	99.21%	97.47%
Risk Free Rate	2.91%	3.03%

Share Based Compensation (Detai

Share Based Compensation (Details Narrative) - USD ($)	Jan. 02, 2018	Apr. 05, 2017	Jan. 31, 2018	Jun. 30, 2017	May 31, 2017	Oct. 31, 2018	Oct. 31, 2017	Mar. 21, 2018	Oct. 31, 2016	Mar. 10, 2016	Sep. 30, 2011
Issuance of common stock			881,629	92,145	92,145
Common stock authorized for issuance						95,000,000	95,000,000
Common stock, shares outstanding						69,556,452	41,206,538
Unrecognized compensation cost related to non-vested stock option awards							$ 2,300,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period						1 year 5 months 12 days	2 years 2 months 5 days
Options outstanding, intrinsic value									$ 62,000
Share-based compensation, common stock, value						77,000	1,600,000
Stock compensation expense						$ 6,983,000	$ 27,836,000
Expected dividend yield						0.00%	0.00%
Stock option vested expiration date							Jul. 5, 2021
Compensation cost related to outstanding stock options						$ 3,700,000	$ 17,200,000
Number of stock shares issued during period amount			$ 2,700,000	$ 700,000	$ 700,000
Number of options, granted						2,518,060	556,952
Fair value of option granted						$ 4,100,000	$ 3,500,000
Common stock shares issued						69,556,452	41,206,538
Consultants [Member]
Stock issued during period for services							165,907
Stock issued during period value for services							$ 1,400,000
Restricted Stock Units (RSUs) [Member]
Fair value of equity purchases value						$ 1,600,000	$ 6,000,000
Unrecognized compensation cost related to non-vested stock option awards						1,700,000
Options outstanding, intrinsic value						$ 275,000
Number of options, granted						409,950	1,632,134
Employee Stock Awards [Member]
Share-based compensation, common stock, shares						733,105	878,948
Share-based compensation, shares on net basis after employee payroll taxes						687,448	834,600
Share-based compensation, common stock, value						$ 3,100,000	$ 8,900,000
Stock compensation expense						$ 100,000	$ 300,000
Director Stock Awards [Member]
Share-based compensation, common stock, shares						75,000	30,000
Stock compensation expense						$ 200,000	$ 400,000
2015 Plan [Member]
Shares of common stock outstanding, percentage	5.00%	5.00%
Common stock, shares outstanding	2,066,147	2,500,000
Common stock reserved for issuance under plan						1,525,692
2015 Plan [Member] | Minimum [Member]
Common stock authorized for issuance		4,600,000				45,000,000		65,000,000		3,600,000
2015 Plan [Member] | Maximum [Member]
Common stock authorized for issuance		6,100,000				65,000,000		95,000,000		4,600,000
2011 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance under plan											40,000
Stock issued during period for services							26,594
Stock issued during period value for services							$ 80,000
Common stock shares issued						10,681
Discount price percentage											15.00%
2015 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance under plan						971,510
Employee stock purchase plan description						The Advaxis, Inc. 2015 Employee Stock Purchase Plan ("2015 ESPP") was approved by the Company's shareholders on March 21, 2018. The 2015 ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the 2015 ESPP beginning May 1, 2018. 1,000,000 shares of the Company's Common stock are reserved for issuance under the 2015 ESPP.
Discount price percentage						15.00%
Employee Stock Purchase Plan [Member]
Share-based compensation, common stock, value						$ 7,000
Common stock shares issued						28,490
Additional Shares [Member] | 2015 Plan [Member]
Issuance of common stock						650,000
Stock Split [Member] | 2015 Plan [Member]
Issuance of common stock						3,600,000

Share Based Compensation - Summ

Share Based Compensation - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Share-based compensation expense	$ 6,983	$ 27,836
Research and Development [Member]
Share-based compensation expense	2,836	5,648
General and Administrative [Member]
Share-based compensation expense	$ 4,147	$ 22,188

Share Based Compensation - Su_2

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - $ / shares	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Number of RSUs Granted	2,518,060	556,952
Number of RSUs Cancelled	(1,460,569)	(15,189)
Weighted-Average Grant Date Fair Value, Granted	$ 1.61	$ 6.36
Restricted Stock Units (RSUs) [Member]
Number of RSUs, Beginning Balance	1,363,119	719,448
Number of RSUs Granted	409,950	1,632,134
Number of RSUs Vested	(808,097)	(877,383)
Number of RSUs Cancelled	(475,702)	(111,080)
Number of RSUs, Ending Balance	489,270	1,363,119
Weighted-Average Grant Date Fair Value, Outstanding, Beginning	$ 8.54	$ 10.77
Weighted-Average Grant Date Fair Value, Granted	1.97	7.90
Weighted-Average Grant Date Fair Value, Vested	7.71	9.15
Weighted-Average Grant Date Fair Value, Cancelled	8.23	8.74
Weighted-Average Grant Date Fair Value, Outstanding, Ending	$ 4.69	$ 8.54

Share Based Compensation - Su_3

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) - USD ($)	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Options, Beginning Balance	3,893,558	3,351,795
Number of Options, Granted	2,518,060	556,952
Number of Options, Canceled or Expired	(1,460,569)	(15,189)
Number of Options, Ending Balance	4,951,049	3,893,558
Number of Options, Vested and Exercisable	2,827,171
Weighted-Average Exercise Price, Outstanding, Beginning	$ 12.51	$ 13.31
Weighted-Average Exercise Price, Granted	2.06	7.71
Weighted-Average Exercise Price, Canceled or Expired	9.14	14.07
Weighted-Average Exercise Price, Outstanding, Ending	8.19	$ 12.51
Weighted-Average Exercise Price, Vested and Exercisable	$ 8.19
Weighted-Average Remaining Contractual Life In Years, Beginning	5 years 8 months 19 days	7 years 9 months 25 days
Weighted-Average Remaining Contractual Life In Years, Ending	6 years 6 months 21 days	5 years 8 months 19 days
Weighted-Average Remaining Contractual Life In Years, Vested and Exercisable	4 years 4 months 17 days
Aggregate Intrinsic Value, Beginning		$ 62,000
Aggregate Intrinsic Value, Ending
Aggregate Intrinsic Value, Vested and Exercisable

Share Based Compensation - Su_4

Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) - USD ($)	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2016
Options Outstanding, Number Outstanding	4,951,049	3,893,558	3,351,795
Options Weighted Average Remaining Contractual Term	5 years 8 months 19 days	7 years 9 months 25 days
Options Outstanding, Weighted Average Exercise Price	$ 8.19	$ 12.51	$ 13.31
Options Outstanding, Intrinsic Value			$ 62,000
Options Exercisable, Number Outstanding	2,827,171
Options Exercisable, Weighted Average Exercise Price	$ 8.19
Options Exercisable, Intrinsic Value
Exercise Price Range $0.60 - $4.99 [Member]
Range, lower limit	$ 0.60
Range, upper limit	$ 4.99
Options Outstanding, Number Outstanding	2,037,108
Options Weighted Average Remaining Contractual Term	9 years 6 months 10 days
Options Outstanding, Weighted Average Exercise Price	$ 1.97
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	165,834
Options Weighted Average Remaining Contractual Term Exercisable	7 years 3 months 8 days
Options Exercisable, Weighted Average Exercise Price	$ 3.22
Options Exercisable, Intrinsic Value
Exercise Price Range $5.00 - $9.99 [Member]
Range, lower limit	$ 5
Range, upper limit	$ 9.99
Options Outstanding, Number Outstanding	526,029
Options Weighted Average Remaining Contractual Term	5 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price	$ 7.98
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	393,424
Options Weighted Average Remaining Contractual Term Exercisable	4 years 4 months 13 days
Options Exercisable, Weighted Average Exercise Price	$ 8.07
Options Exercisable, Intrinsic Value
Exercise Price Range $10.00 - $14.99 [Member]
Range, lower limit	$ 10
Range, upper limit	$ 14.99
Options Outstanding, Number Outstanding	2,199,592
Options Weighted Average Remaining Contractual Term	4 years 5 months 1 day
Options Outstanding, Weighted Average Exercise Price	$ 13.14
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	2,079,593
Options Weighted Average Remaining Contractual Term Exercisable	4 years 3 months 8 days
Options Exercisable, Weighted Average Exercise Price	$ 13.16
Options Exercisable, Intrinsic Value
Exercise Price Range $15.00 - $21.25 [Member]
Range, lower limit	$ 15
Range, upper limit	$ 21.25
Options Outstanding, Number Outstanding	188,320
Options Weighted Average Remaining Contractual Term	3 years 26 days
Options Outstanding, Weighted Average Exercise Price	$ 18.12
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	188,320
Options Weighted Average Remaining Contractual Term Exercisable	3 years 26 days
Options Exercisable, Weighted Average Exercise Price	$ 18.12
Options Exercisable, Intrinsic Value

Share Based Compensation - Su_5

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) - $ / shares	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Weighted average fair value of options granted	$ 1.61	$ 6.36
Expected volatility, minimum	91.14%	107.07%
Expected volatility, maximum	100.34%	110.93%
Expected dividends	0.00%	0.00%
Risk free interest rate, minimum	1.81%	1.26%
Risk free interest rate, maximum	3.16%	1.58%
Minimum [Member]
Expected term	5 years 4 months 6 days	5 years 6 months
Maximum [Member]
Expected term	6 years 6 months 3 days	6 years 6 months

Collaboration and Licensing A_2

Collaboration and Licensing Agreements (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Aug. 02, 2016	Feb. 03, 2016	Mar. 19, 2014	Dec. 09, 2013	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2014	Oct. 31, 2016
Number of common stock shares					69,556,452	41,206,538
Warrants outstanding					14,169,542	3,092,395		3,110,575
Warrant exercise price					$ 1.50
Warrants exercised						(225)
Amgen Agreement [Member]
Upfront payment	$ 40,000
Value of stock purchased	25,000
Development, regulatory and sales milestone payments	475,000
Upfront payment recorded as deferred revenue	$ 40,000
Business combination amount transferred					$ 5,800	$ 11,800
Number of common stock shares	3,047,446
Common stock purchase price per share	$ 8.20
Proceeds from issuance of stock	$ 25,000
Reduction in research and development expenses					5,800	7,500
Stendhal Agreement [Member]
Support payments expenses		$ 10,000				3,000
Aratana Agreement [Member]
Upfront payment			$ 1,000
Development, regulatory and sales milestone payments			$ 36,500
Number of common stock shares			306,122
Common stock purchase price per share			$ 4.90
Proceeds from royalty received					5
Licensing revenue							$ 1,000
Additional, cumulative sales milestone payments			$ 15,000
Aratana Agreement [Member] | Warrants [Member]
Number of common stock shares			153,061
Common stock purchase price per share			$ 4.90
Proceeds from issuance of stock			$ 1,500
Warrants outstanding			153,061
Warrant term			10 years
Merck Agreement [Member]
Agreement expenses					2,400	2,900
MedImmune Agreement [Member]
Agreement expenses					2,700	2,800
Global BioPharma, Inc [Member]
Value of stock purchased				$ 400
Number of common stock shares				108,724
Common stock purchase price per share				$ 3.68
Licensing revenue					250	$ 250
Warrants expire date				Dec. 31, 2018
Warrants exercised				100,000
Reimbursement value					$ 2,250
Global BioPharma, Inc [Member] | Warrants [Member]
Warrants outstanding				100,000
Warrant exercise price				$ 5.52

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Sep. 19, 2018	Aug. 21, 2015	Oct. 31, 2018	Oct. 31, 2017
Rent expense			$ 1,200	$ 1,200
Corporate Office & Manufacturing Facility Lease [Member]
Operating lease expiring date			Nov. 30, 2025
KCM [Member]
Number of shares complaint alleges of common stock		1,666,666.67
Common stock price per share		$ 3
Especificos Stendhal SA de CV [Member]
Damages sought value by plaintiff	$ 3,000
Litigation expense	300
Due from related party	$ 3,000

Commitments and Contingencies -

Commitments and Contingencies - Summary of Future Minimum Payments of Operating Leases (Details) $ in Thousands	Oct. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,019	$ 1,107
2,020	1,233
2,021	1,318
2,022	1,369
2,023	1,395
Thereafter	2,983
Total	$ 9,405

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	Dec. 22, 2017	Jan. 31, 2018	Oct. 31, 2018	Oct. 31, 2017
Net operating loss carry-forward			$ 265,800	$ 187,400
Operating loss expiration year			2,023
Total net operating loss carry-forward			$ 290,600
Net operating loss and deferred tax asset does not include nol's			24,800
New jersey state net operating loss carryovers			129,200
Income tax reconciliation description	The U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"). The Tax Act made broad and significant changes to the U.S. tax code including, but not limited to, a change in the federal rate from 34% to 21%. As a result of the enactment of the legislation, the Company recorded a one-time reduction to its deferred tax assets of approximately $34.4 million, which was offset by a reduction in the valuation allowance. When a U.S. federal tax rate change occurs during a fiscal year, taxpayers are required to compute a weighted daily average rate for the fiscal year of enactment. As a result of the Tax Act, Advaxis has calculated a blended U.S. federal statutory corporate income tax rate of approximately 23% for the year ended October 31, 2018 and applied this rate in computing the income tax provision for year ending October 31, 2018. The blended U.S. federal statutory corporate income tax rate of 23% is the weighted daily average rate between the pre-enactment U.S. federal statutory tax rate of 34% applicable to the Company's 2018 fiscal year prior to the Effective Date and the post-enactment U.S. federal statutory tax rate of 21% applicable to the 2018 fiscal year thereafter. Advaxis expects the U.S. federal statutory rate to be 21% for fiscal years beginning after October 31, 2018.
Deferred tax assets	$ 34,400		$ 89,760	$ 107,185
Income tax effective tax rate	21.00%		0.00%	4.55%
Net cash amount received from sale of net operating losses and research and development tax credits		$ 4,500
Internal Revenue Code [Member]
Net operating loss carry-forward			$ 265,800

Income Taxes - Components of In

Income Taxes - Components of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Income Tax Disclosure [Abstract]
Current Federal
Deferred Federal	22,325	(34,296)
Current State and Local		(4,453)
Deferred State and Local	(5,449)	(1,124)
Change in valuation allowance	(16,876)	35,420
Income tax provision (benefit)	$ 50	$ (4,403)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Oct. 31, 2018	Dec. 22, 2017	Oct. 31, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 65,002		$ 66,681
Stock-based compensation	12,081		21,921
Research and development credits	6,843		7,293
Deferred revenue	5,247		9,775
Other deferred tax assets	587		1,515
Total deferred tax assets	89,760	$ 34,400	107,185
Valuation allowance	(87,862)		(104,738)
Deferred tax asset, net of valuation allowance	1,898		2,447
Other deferred tax liabilities	(1,898)		(2,447)
Total deferred tax liabilities	(1,898)		(2,447)
Net deferred tax asset (liability)

Income Taxes - Reconciliation E

Income Taxes - Reconciliation Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit (Details)	Dec. 22, 2017	Oct. 31, 2018	Oct. 31, 2017
Income Tax Disclosure [Abstract]
US Federal statutory rate		23.17%	34.00%
State income tax, net of federal benefit		8.19%	1.15%
Permanent differences		1.22%	(2.30%)
Research and development credits		(0.38%)	2.36%
Income tax benefit from sale of New Jersey NOL carryovers		0.00%	4.55%
Change in valuation allowance		25.37%	(36.20%)
Tax Cuts and Jobs Act		(53.93%)	0.00%
Other		(3.64%)	0.99%
Income tax (provision) benefit	21.00%	0.00%	4.55%

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Sep. 30, 2018	Feb. 28, 2018	Jan. 31, 2018	Jun. 30, 2017	May 31, 2017	Oct. 31, 2018	Oct. 31, 2017
Number of common stock shares sold			881,629	92,145	92,145
Proceeds from sale of common shares			$ 2,700	$ 700	$ 700
Warrants to purchase common stock						14,169,542	3,092,395
Warrant exercise price						$ 1.50
IPO [Member]
Number of common stock shares sold	16,666,666
Proceeds from sale of common shares	$ 20,000
Sale of stock price per share	$ 1.20
Warrants to purchase common stock	0.85
Warrant expiration term	6 years
Warrant exercise price	$ 1.50
Proceeds from registered direct offering, net of offering expenses	$ 18,200
IPO [Member] | Maximum [Member]
Warrants to purchase common stock	14,166,666
Underwriting Agreement [Member]
Number of common stock shares sold		10,000,000
Proceeds from sale of common shares		$ 20,000
Sale of stock price per share		$ 2
Sale of stock transaction during period, value		$ 18,400
Number of common stock purchased		807,697

Fair Value - Schedule of Fair V

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Oct. 31, 2018	Oct. 31, 2017
Common stock warrant liability, warrants exercisable at $1.50 through September 2024	$ 6,517
Fair Value, Inputs, Level 1 [Member]
Common stock warrant liability, warrants exercisable at $1.50 through September 2024
Fair Value, Inputs, Level 2 [Member]
Common stock warrant liability, warrants exercisable at $1.50 through September 2024
Fair Value, Inputs, Level 3 [Member]
Common stock warrant liability, warrants exercisable at $1.50 through September 2024	$ 6,517

Fair Value - Schedule of Fair_2

Fair Value - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) (Parenthetical)	Oct. 31, 2018$ / shares
Fair Value Disclosures [Abstract]
Exercise price of warrants	$ 1.50

Fair Value - Schedule of Change

Fair Value - Schedule of Changes in the Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
Beginning balance
Change in fair value	6,500	$ 0
Ending Balance	6,517
Warrant Liability [Member]
Beginning balance
Issuance of warrants	9,917
Change in fair value	(3,400)
Ending Balance	$ 6,517

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
401(k) Plan [Member]
Employee contributions, amount	$ 400	$ 400

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Nov. 05, 2018	Oct. 31, 2018	Oct. 31, 2017
Exercise price		$ 2.06	$ 7.71
Reimbursement expense		$ 5,800	$ 7,500
Subsequent Event [Member] | Executives [Member]
Number of stock option grants	720,000
Exercise price	$ 0.54
Subsequent Event [Member] | Non Executive Directors [Member]
Number of stock option grants	130,000
Exercise price	$ 0.54